Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Novel Monoclonal Antibody Under Study for Peripheral T-Cell Lymphomas

By: Joseph Fanelli
Posted: Monday, July 22, 2019

Investigators are set to enroll patients in the TELLOMAK phase II study, to investigate the anti-KIR3DL2 monoclonal antibody IPH4102 and its safety and clinical impact on patients with peripheral T-cell lymphomas, according to presenters at the 2019 International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (Abstract OT06). IPH4102, which is designed to deplete KIR3DL2-expressing cells with cell cytotoxicity and phagocytosis, has previously demonstrated “robust clinical activity” in treating patients with relapsed or refractory cutaneous T-cell lymphoma, according to Pierluigi Porcu, MD, Director of the Division of Medical Oncology and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, Philadelphia, and colleagues. The phase I study findings were published recently in The Lancet Oncology.

Phase II of the trial, an open-label, multicohort, multicenter study, will assign patients into five cohorts. Cohort one will consist of patients diagnosed with Sézary syndrome, cohorts two and three are for patients with mycosis fungoides and will be stratified by KIR3DL2 expression, and the final two cohorts will consist of patients diagnosed with peripheral T-cell lymphomas and will also be stratified by KIR3DL2 expression. Patients with Sézary syndrome or mycosis fungoides will receive IPH4102 as a single agent at a flat dose of 750 mg every week for 4 weeks, then every 2 weeks for 20 weeks, and finally every 4 weeks. For those patients with peripheral T-cell lymphomas, the novel agent will be delivered using that same schedule with the addition of gemcitabine and oxaliplatin.

Previously, preclinical trials demonstrated that gemcitabine and oxaliplatin can upregulate KIR3DL2 expression on T-cell lymphoma cell lines. According to the presenters, these trials also showed that IPH4102 antitumor activity was enhanced in vitro by those chemotherapy agents, and even more when used in combination.

Disclosure: The study authors’ disclosure information can be found at lymphcon.ch.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.